Diagnostic Approach for Chronic Leukocytosis

Initial Laboratory Evaluation

The initial workup for chronic leukocytosis should include a complete blood count with differential, peripheral blood smear examination, bone marrow aspirate and biopsy, and cytogenetic/molecular testing to determine the underlying cause and guide appropriate management, as recommended by the European Society for Medical Oncology 1
A complete blood count (CBC) with differential is necessary to quantify the degree of leukocytosis and identify which cell lineage is predominantly affected, according to the National Comprehensive Cancer Network 2
Peripheral blood smear examination is used to assess cell morphology and identify abnormal cells, as suggested by the European Society for Medical Oncology 1
Chemistry profile including LDH, bilirubin, and renal function tests should be performed, as recommended by the European Society for Medical Oncology 3, 4
Serum protein electrophoresis is used to evaluate for monoclonal proteins, as suggested by the European Society for Medical Oncology 4, 5
Direct antiglobulin test (Coombs test) is used to assess for autoimmune hemolytic anemia, as recommended by the European Society for Medical Oncology 1, 4

Bone marrow aspirate and biopsy are necessary for morphologic assessment, particularly before initiating therapy, as recommended by the European Society for Medical Oncology 1, 2
Immunophenotyping by flow cytometry is used to characterize abnormal cells, as suggested by the European Society for Medical Oncology 1, 6
Cytogenetic analysis with FISH is used to detect chromosomal abnormalities with prognostic significance, as recommended by the European Society for Medical Oncology 3, 4
Molecular studies for specific genetic markers, such as BCR-ABL for CML, should be performed, as suggested by the National Comprehensive Cancer Network 2

Chronic lymphocytic leukemia (CLL) is characterized by ≥5 × 10^9/L mature-appearing lymphocytes with specific immunophenotype, as defined by the European Society for Medical Oncology 1, 4
Chronic myeloid leukemia (CML) often presents with basophilia, immature granulocytes, and BCR-ABL fusion gene, as described by the National Comprehensive Cancer Network 2
Other lymphoproliferative disorders, including mantle cell lymphoma, require differential diagnosis from CLL, as recommended by the European Society for Medical Oncology 1, 5

Sustained lymphocytosis ≥5 × 10^9/L with predominance of small, mature lymphocytes is diagnostic for CLL, as defined by the European Society for Medical Oncology 1, 6
Characteristic immunophenotype, including CD5+, CD19+, CD20+ (low), CD23+, surface immunoglobulin (sIg) low, CD79b low, FMC7–, is necessary for CLL diagnosis, as recommended by the European Society for Medical Oncology 1, 7
Bone marrow biopsy is not required for CLL diagnosis but is recommended before treatment initiation, as suggested by the European Society for Medical Oncology 1, 4

Cytogenetic abnormalities by FISH have significant prognostic value in CLL, as recommended by the European Society for Medical Oncology 1, 4
Del(17p) or p53 mutations indicate poor prognosis and altered treatment approach in CLL, as described by the European Society for Medical Oncology 4, 6
Clinical staging using Binet or Rai systems helps determine prognosis and treatment needs in CLL, as recommended by the European Society for Medical Oncology 4, 7

Early-stage CLL (Binet A/B without symptoms, Rai 0-II without symptoms) can be managed with a watch and wait strategy with monitoring every 3-6 months, as recommended by the European Society for Medical Oncology 4, 6
Advanced or symptomatic CLL requires treatment options based on patient fitness, comorbidities, and cytogenetic profile, as suggested by the European Society for Medical Oncology 4, 7
Fludarabine, cyclophosphamide, and rituximab (FCR) combination is a treatment option for fit patients with CLL, as recommended by the European Society for Medical Oncology 4, 6
Chlorambucil or reduced-dose purine analog therapy can be used for patients with comorbidities, as suggested by the European Society for Medical Oncology 4, 6
Tyrosine kinase inhibitors are the standard first-line therapy for CML, as recommended by the National Comprehensive Cancer Network 2